From Wikipedia, the free encyclopedia
Content deleted Content added
|
 |
|||
| Line 2: | Line 2: | ||
|
{{CS1 config|mode=cs1}} |
{{CS1 config|mode=cs1}} |
||
|
”’Effector tumor antigen–specific T cells”’ (ETASTs) are a specialized group of immune cells that can both recognize and kill cancer cells. They arise from the larger group of tumor antigen–specific T cells (TASTs), which are [[lymphocytes]] trained to detect specific antigens expressed by tumors. The amount of polyclonal TASTs (especially effector tumor antigen-specific T cells (ETASTs) can be used as [[biomarkers]] for therapeutic efficacy prediction of [[immunotherapy]]/[[chemoimmunotherapy]] combinations.<ref>{{Cite journal |last1=Ahmadzadeh |first1=Mojgan |last2=Johnson |first2=Laura A. |last3=Heemskerk |first3=Bianca |last4=Wunderlich |first4=John R. |last5=Dudley |first5=Mark E. |last6=White |first6=Donald E. |last7=Rosenberg |first7=Steven A. |date=2009-08-20 |title=Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired |url=https://ashpublications.org/blood/article/114/8/1537/26336/Tumor-antigenspecific-CD8-T-cells-infiltrating-the |journal=Blood |language=en |volume=114 |issue=8 |pages=1537–1544 |doi=10.1182/blood-2008-12-195792 |issn=0006-4971 |pmc=2927090 |pmid=19423728}}</ref> |
”’Effector tumor antigen–specific T cells”’ (ETASTs) are a specialized group of immune cells that can both recognize and kill cancer cells. They arise from the larger group of tumor antigen–specific T cells (TASTs), which are [[lymphocytes]] trained to detect specific antigens expressed by tumors. The amount of polyclonal TASTs (especially effector tumor antigen-specific T cells (ETASTs) can be used as [[biomarkers]] for therapeutic efficacy prediction of [[immunotherapy]]/[[chemoimmunotherapy]] combinations.<ref>{{Cite journal |last1=Ahmadzadeh |first1=Mojgan |last2=Johnson |first2=Laura A. |last3=Heemskerk |first3=Bianca |last4=Wunderlich |first4=John R. |last5=Dudley |first5=Mark E. |last6=White |first6=Donald E. |last7=Rosenberg |first7=Steven A. |date=2009-08-20 |title=Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired |url=https://ashpublications.org/blood/article/114/8/1537/26336/Tumor-antigenspecific-CD8-T-cells-infiltrating-the |journal=Blood |language=en |volume=114 |issue=8 |pages=1537–1544 |doi=10.1182/blood-2008-12-195792 |issn=0006-4971 |pmc=2927090 |pmid=19423728}}</ref> |
||
|
Such tumor antigen-specific T cells can be isolated through nanoparticles loading whole tumor antigens and CD137 marker(https://doi.org/10.1016/j.intimp.2025.115695). These isolated and expanded ETAST can be used as therapeutic T cells(https://doi.org/10.1016/j.intimp.2025.115695). |
|||
|
==Categorisation== |
==Categorisation== |
||
Latest revision as of 04:24, 19 October 2025
Effector tumor antigen–specific T cells (ETASTs) are a specialized group of immune cells that can both recognize and kill cancer cells. They arise from the larger group of tumor antigen–specific T cells (TASTs), which are lymphocytes trained to detect specific antigens expressed by tumors. The amount of polyclonal TASTs (especially effector tumor antigen-specific T cells (ETASTs) can be used as biomarkers for therapeutic efficacy prediction of immunotherapy/chemoimmunotherapy combinations.[1]
Such tumor antigen-specific T cells can be isolated through nanoparticles loading whole tumor antigens and CD137 marker(https://doi.org/10.1016/j.intimp.2025.115695). These isolated and expanded ETAST can be used as therapeutic T cells(https://doi.org/10.1016/j.intimp.2025.115695).
Based on structural and functional specificity, TASTs were categorized into three groups:
- Effector Tumor Antigen-Specific T Cells (ETASTs) are both specifically recognize tumor antigens and specifically kill tumor cells containing the corresponding antigen after recognition of the tumor antigen.
- Regulatory tumor antigen-specific T cells (RTASTs) can only specifically recognize tumor antigens, but instead of killing cancer cells after recognition, they inhibit the function of ETASTs.[2]
- Anergy tumor antigen-specific T cells (ATASTs) can only specifically recognize tumor antigens, but do not have the function of killing tumor cells after recognition.[3]
Use as biomarker in cancer treatment
[edit]
Recent studies have shown a positive correlation between the levels of polyclonal ETASTs in vivo or in peripheral blood and the efficacy and prognosis of combined immunotherapy/chemoimmunotherapy in cancer patients after combined immunotherapy/chemoimmunotherapy. Polyclonal ETASTs are the mainstay of the body’s specific recognition and specific killing of cancer cells, and are the real players in immunotherapy. Successful immunotherapy relies on reactivating or increasing the levels of polyclonal ETASTs.[4]
Detection of polyclonal ETASTs in the peripheral blood of cancer patients may be an ideal biomarker to predict the efficacy and prognosis of combined immunotherapy/chemoimmunotherapy.[5]
Although these T cells can specifically recognize tumor antigens, not all TASTs have cytotoxic functions. Specific recognition of tumor antigens is structural specificity, whereas the ability to kill tumor cells containing such antigens after recognition is functional specificity.[6]
- ^ Ahmadzadeh, Mojgan; Johnson, Laura A.; Heemskerk, Bianca; Wunderlich, John R.; Dudley, Mark E.; White, Donald E.; Rosenberg, Steven A. (2009-08-20). “Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired”. Blood. 114 (8): 1537–1544. doi:10.1182/blood-2008-12-195792. ISSN 0006-4971. PMC 2927090. PMID 19423728.
- ^ “Antigen-Specific Cell Enrichment”. SpringerReference. Berlin/Heidelberg: Springer-Verlag. 2011. doi:10.1007/springerreference_31813 (inactive 1 July 2025). Retrieved 2025-03-28.
{{citation}}: CS1 maint: DOI inactive as of July 2025 (link) - ^ Jenkins, M K; Chen, C A; Jung, G; Mueller, D L; Schwartz, R H (1990-01-01). “Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody”. The Journal of Immunology. 144 (1): 16–22. doi:10.4049/jimmunol.144.1.16. ISSN 0022-1767. PMID 2153162.
- ^ https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202409913; https://pubs.acs.org/doi/10.1021/acs.analchem.4c04049
- ^ Wang, Jin; Zeng, Weibiao; Xue, Jiao; Zhu, Ao; Chen, Xianlan; Zheng, Yan; Liu, Yuhan; Qin, Songbing; Zhao, Jun; Liu, Mi (2024-12-03). “Efficient Biomarker for Immunotherapy: Measuring Broad Clones Effector Tumor Antigen-Specific T Cells in the Blood of Esophageal Cancer Patients”. Analytical Chemistry. 96 (48): 19056–19065. Bibcode:2024AnaCh..9619056W. doi:10.1021/acs.analchem.4c04049. ISSN 0003-2700. PMID 39561375.
- ^ Zeng, Weibiao; Wang, Jin; Chen, Zhike; Yang, Jian; Zhu, Ao; Zheng, Yan; Chen, Xianlan; Liu, Yuhan; Wu, Leilei; Xie, Yufeng; Ju, Sheng; Chen, Jun; Ding, Cheng; Li, Chang; Tong, Xin (January 2025). “Efficient Predictor for Immunotherapy Efficacy: Detecting Pan-Clones Effector Tumor Antigen-Specific T Cells in Blood by Nanoparticles Loading Whole Tumor Antigens”. Advanced Science. 12 (2) e2409913. doi:10.1002/advs.202409913. ISSNÂ 2198-3844. PMCÂ 11727128. PMIDÂ 39498880.
